The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3

Murali Janakiram; Urvi A. Shah; Weifeng Liu; Aimin Zhao; Mark P. Schoenberg; Xingxing Zang

doi:10.1111/imr.12521

The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3

Murali Janakiram, Urvi A. Shah, Weifeng Liu, Aimin Zhao, Mark P. Schoenberg, Xingxing Zang

Research output: Contribution to journal › Review article › peer-review

182 Scopus citations

Abstract

The B7-CD28 family of ligands and receptors play important roles in T-cell co-stimulation and co-inhibition. Phylogenetically they can be divided into three groups. The recent discovery of the new molecules (B7-H3 [CD276], B7x [B7-H4/B7S1], and HHLA2 [B7H7/B7-H5]/TMIGD2 [IGPR-1/CD28H]) of the group III has expanded therapeutic possibilities for the treatment of human diseases. In this review, we describe the discovery, structure, and function of B7-H3, B7x, HHLA2, and TMIGD2 in immune regulation. We also discuss their roles in important pathological states such as cancers, autoimmune diseases, transplantation, and infection. Various immunotherapeutical approaches are emerging including antagonistic monoclonal antibodies and agonistic fusion proteins to inhibit or potentiate these molecules and pathways in cancers and autoimmune diseases.

Original language	English (US)
Pages (from-to)	26-39
Number of pages	14
Journal	Immunological Reviews
Volume	276
Issue number	1
DOIs	https://doi.org/10.1111/imr.12521
State	Published - Mar 1 2017

Keywords

B7-H3
B7x
HHLA2
TMIGD2
immune checkpoint
immunotherapy

ASJC Scopus subject areas

Immunology and Allergy
Immunology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/imr.12521

Cite this

@article{b981da2803a84726bc86f772939788fb,

title = "The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3",

abstract = "The B7-CD28 family of ligands and receptors play important roles in T-cell co-stimulation and co-inhibition. Phylogenetically they can be divided into three groups. The recent discovery of the new molecules (B7-H3 [CD276], B7x [B7-H4/B7S1], and HHLA2 [B7H7/B7-H5]/TMIGD2 [IGPR-1/CD28H]) of the group III has expanded therapeutic possibilities for the treatment of human diseases. In this review, we describe the discovery, structure, and function of B7-H3, B7x, HHLA2, and TMIGD2 in immune regulation. We also discuss their roles in important pathological states such as cancers, autoimmune diseases, transplantation, and infection. Various immunotherapeutical approaches are emerging including antagonistic monoclonal antibodies and agonistic fusion proteins to inhibit or potentiate these molecules and pathways in cancers and autoimmune diseases.",

keywords = "B7-H3, B7x, HHLA2, TMIGD2, immune checkpoint, immunotherapy",

author = "Murali Janakiram and Shah, {Urvi A.} and Weifeng Liu and Aimin Zhao and Schoenberg, {Mark P.} and Xingxing Zang",

note = "Publisher Copyright: {\textcopyright} 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd",

year = "2017",

month = mar,

day = "1",

doi = "10.1111/imr.12521",

language = "English (US)",

volume = "276",

pages = "26--39",

journal = "Immunological Reviews",

issn = "0105-2896",

publisher = "Wiley-Blackwell",

number = "1",

}

TY - JOUR

T1 - The third group of the B7-CD28 immune checkpoint family

T2 - HHLA2, TMIGD2, B7x, and B7-H3

AU - Janakiram, Murali

AU - Shah, Urvi A.

AU - Liu, Weifeng

AU - Zhao, Aimin

AU - Schoenberg, Mark P.

AU - Zang, Xingxing

PY - 2017/3/1

Y1 - 2017/3/1

N2 - The B7-CD28 family of ligands and receptors play important roles in T-cell co-stimulation and co-inhibition. Phylogenetically they can be divided into three groups. The recent discovery of the new molecules (B7-H3 [CD276], B7x [B7-H4/B7S1], and HHLA2 [B7H7/B7-H5]/TMIGD2 [IGPR-1/CD28H]) of the group III has expanded therapeutic possibilities for the treatment of human diseases. In this review, we describe the discovery, structure, and function of B7-H3, B7x, HHLA2, and TMIGD2 in immune regulation. We also discuss their roles in important pathological states such as cancers, autoimmune diseases, transplantation, and infection. Various immunotherapeutical approaches are emerging including antagonistic monoclonal antibodies and agonistic fusion proteins to inhibit or potentiate these molecules and pathways in cancers and autoimmune diseases.

AB - The B7-CD28 family of ligands and receptors play important roles in T-cell co-stimulation and co-inhibition. Phylogenetically they can be divided into three groups. The recent discovery of the new molecules (B7-H3 [CD276], B7x [B7-H4/B7S1], and HHLA2 [B7H7/B7-H5]/TMIGD2 [IGPR-1/CD28H]) of the group III has expanded therapeutic possibilities for the treatment of human diseases. In this review, we describe the discovery, structure, and function of B7-H3, B7x, HHLA2, and TMIGD2 in immune regulation. We also discuss their roles in important pathological states such as cancers, autoimmune diseases, transplantation, and infection. Various immunotherapeutical approaches are emerging including antagonistic monoclonal antibodies and agonistic fusion proteins to inhibit or potentiate these molecules and pathways in cancers and autoimmune diseases.

KW - B7-H3

KW - B7x

KW - HHLA2

KW - TMIGD2

KW - immune checkpoint

KW - immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=85014391455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014391455&partnerID=8YFLogxK

U2 - 10.1111/imr.12521

DO - 10.1111/imr.12521

M3 - Review article

C2 - 28258693

AN - SCOPUS:85014391455

SN - 0105-2896

VL - 276

SP - 26

EP - 39

JO - Immunological Reviews

JF - Immunological Reviews

IS - 1

ER -

The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this